Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?
Warner
Timothy D
TD
The William Harvey Research Institute, Bart's and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, United Kingdom. t.d.warner@qmul.ac.uk
Mitchell
Jane A
JA
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D014644:Genetic Variation; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D008565:Membrane Proteins; D008954:Models, Biological; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects* / Q000235:genetics*; D011453:Prostaglandins / Q000096:biosynthesis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011453:Prostaglandins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C466421:cyclooxygenase-3